ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i3.1003ppharm-92Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWКЛИНИКО-ФАРМАКОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ПРИМЕНЕНИЯ ЦЕТИРИЗИНА В ТЕРАПИИ АЛЛЕРГИЧЕСКИХ БОЛЕЗНЕЙ У ДЕТЕЙCLINICAL AND PHARMACOLOGICAL PECULIARITIES OF CETIRIZINE USE FOR THE THERAPY OF ALLERGIC DISEASES IN CHILDRENЛевинаЮ. Г.LevinaYu. G.

кандидат медицинских наук, заведующая отделом стандартизации и клинической фармакологии, доцент кафедры аллергологии и клинической иммунологии педиатрического факультета Первого МГМУ им. И.М. Сеченова

MD, head of the department of standardization and clinical pharmacology, assistant professor at the department of allergology and clinical immunology of the pediatric faculty of I.M. Sechenov First Moscow State Medical University

levina@nczd.ruНамазова-БарановаЛ. С.Namazova-BaranovaL. S.АлексееваА. А.AlexeevaA. A.ВишнёваЕ. А.VishnevaE. A.ЭфендиеваК. Е.EfendievaK. E.ТомиловаА. Ю.TomilovaA. Y.Научный центр здоровья детей, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Moscow Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская Федерация Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian Federation Pirogov Russian National Medical Research University, MoscowRussian FederationНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201403062014113Педиатрическая фармакология2026Copyright © Левина Ю.Г., Намазова-Баранова Л.С., Алексеева А.А., Вишнёва Е.А., Эфендиева К.Е., Томилова А.Ю., 20142014Левина Ю.Г., Намазова-Баранова Л.С., Алексеева А.А., Вишнёва Е.А., Эфендиева К.Е., Томилова А.Ю.Levina Y.G., Namazova-Baranova L.S., Alexeeva A.A., Vishneva E.A., Efendieva K.E., Tomilova A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/92

The review is dedicated to treatment of allergic diseases in children, particularly to the use of the 2nd generation antihistamine. It demonstrates that mediator histamine has the crucial role in pathophysiology of the allergic reaction. Antihistamines block histamine action aimed at H1 receptors by way of competitive inhibition. The 2nd generation antihistamines are the drugs of choice for the treatment of allergic diseases due to the absence of sedative effect. The review presents clinical and pharmacological description of the selective 2nd generation antihistamine cetirizine, efficacy and safety of which have been appraised in numerous long-term clinical studies in children with allergic rhinitis, urticaria and atopic dermatitis.

 

антигистаминные препаратыцетиризиндетиаллергический ринитатопический дерматитantihistaminescetirizinechildrenallergic rhinitisatopic dermatitisReferencesНамазова-Баранова Л. С. Аллергия у детей — от теории к практике. Москва. 2010. 668 с.Namazova-Baranova L. S. Allergiya u detei — ot teorii k praktike [Allergy in Children – from Theory to Practice]. Moscow, 2010. 668 p.Вишнёва Е. А., Алексеева А. А., Геворкян А. К. Применение дезлоратадина при аллергическом рините и сопутствующей бронхиальной астме у детей. Педиатрическая фармакология. 2008; 5 (2): 33–37.Vishneva E. A., Alexeeva A. A., Gevorkyan A. K. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (2): 33–37.Полосьянц О. Б., Силина Е. Г., Намазова Л. С. Антигистаминные препараты: от димедрола к телфасту. Лечащий врач. 2001; 3.Polos'yants O.B., Silina E.G., Namazova L.S. Lechashchii vrach = Practicing doctor. 2001; 3.Намазова-Баранова Л. С. Смертность от антигистаминных препаратов первого поколения. Позиция регуляторных органов. Позиция врача-педиатра. Педиатрическая фармакология. 2009; 3: 52.Namazova-Baranova L. S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 3: 52.Аллергология и иммунология. Под общей редакциейAllergologiya i immunologiya. Pod obshchei redaktsiei A.A. Baranova i R.M. Khaitova [Allergology and Immunology. Edited by A.A. Baranov, R.M. Khaitov]. Moscow, 2008–2009. p. 75.А. А. Баранова и Р. М. Хаитова. Москва. 2008–2009. С. 75.Vishneva E. A. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 6 (1): 70–74.Вишнёва Е. А. Неседативные антигистаминные препараты при аллергических болезнях у детей. Дезлоратадин. Педиатрическая фармакология. 2009; 6 (1): 70–74.Monique P. Curran, Lesley J. Scott, Caroline M. Perry. Cetirizine A. Review of its Use in Allergic Disorders. Drugs. 2004; 64 (5): 523–561.Monique P. Curran, Lesley J. Scott, Caroline M. Perry. Cetirizine A. Review of its Use in Allergic Disorders. Drugs. 2004; 64 (5): 523–561.Gushchin I.S. Tsetirizin — etalon N1-antigistaminnogo sredstva (Cetirizine – Reference H1-Antihistamine). Available at: www.health-medix.com. 2009; 5 (61): 60–70.Гущин И. С. Цетиризин — эталон Н1-антигистаминного средства. www.health-medix.com. 2009; 5 (61): 60–70.Simons F. E., Johnston L., Simons K. J. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr. Allergy Immunol. 2000 May; 11 (2): 116–9.Simons F. E., Johnston L., Simons K. J. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr Allergy Immunol. 2000 May; 11 (2): 116–9.Simons F. E., Semus M., Goritz S. S., Simons K. J. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr. Allergy Immunol. 2003 Jun; 14 (3): 207–11.Simons F. E., Semus M., Goritz S. S., Simons K. J. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol. 2003 Jun; 14 (3): 207–11.Koller M., Hilger R. A., Rihoux J. P. et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int. Arch. Allergy Immunol. 1996 May; 110 (1): 52–56.Koller M., Hilger R. A., Rihoux J. P. et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int Arch Allergy Immunol. 1996 May; 110 (1): 52–6.Kondyurina E.G., Elkina T.N., Gribanova O.A. Russkii meditsinskii zhurnal = Russian medical journal. 2013; 2: 63–65.Кондюрина Е. Г., Ёлкина Т. Н., Грибанова О. А. Цетиризин в практике педиатра. Русский медицинский журнал. 2013; 2: 63–65.Di Gioacchino M., Verna N., Cavallucci E. et al. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. Int. J. Immunopathol. Pharmacol. 2002 Jan; 15 (1): 27–34.Di Gioacchino M., Verna N., Cavallucci E. et al. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. Int J Immu nopathol Pharmacol. 2002 Jan; 15 (1): 27–34.Dobashi K., Iizuka K., Houjou S. et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann. Allergy Asthma Immunol. 1996 Oct; 77 (4): 310–318.Dobashi K., Iizuka K., Houjou S. et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann Allergy Asthma Immunol. 1996 Oct; 77 (4): 310–8.Pfizer Inc. Zyrtec (cetirizine hydrochloride): tablets and syrup. For oral use [US prescribing information]. New York, Pfizer Inc., 2003.Pfizer Inc. Zyrtec (cetirizine hydrochloride): tablets and syrup. For oral use [US prescribing information]. New York: Pfizer Inc. 2003.Ferrer M.1., Morais-Almeida M., Guizova M., Khanferyan R. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non–interventional, retrospective study. Clin. Drug. Investig. 2010; 30 (1): 15–34.Ferrer M.1., Morais-Almeida M., Guizova M., Khanferyan R. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non–interventional, retrospective study. Clin Drug Investig. 2010; 30 (1): 15–34.Stevenson J., Cornah D., Evrard P. et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr. Res. 2002 Aug; 52 (2): 251–257.Stevenson J., Cornah D., Evrard P. et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res. 2002 Aug; 52 (2): 251–7.Simons F. E. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis: ETAC Study Group. Early Treatment of the Atopic Child. J. Allergy Clin. Immunol. 1999 Aug; 104 (2 Pt. 1): 433–440.Simons F. E. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis: ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol. 1999 Aug; 104 (2 Pt. 1): 433–40.Winder J. A., Noonan M. J., Lumry W. R. et al. Absence of QT (c) prolongation with cetirizine in children aged 6 to 11 years. Pediatr. Asthma Allergy Immunology. 1996; 10 (4): 181–190.Winder J. A., Noonan M. J., Lumry W. R. et al. Absence of QT (c) prolongation with cetirizine in children aged 6 to 11 years. Pediatr Asthma Allergy Immunology. 1996; 10 (4): 181–90.Simons F. E., Silas P., Portnoy J. M. et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double blind, placebocontrolled study. J. Allergy Clin. Immunol. 2003 Jun; 111 (6): 1244–1248.Simons F. E., Silas P., Portnoy J. M. et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double blind, placebo-controlled study. J Allergy Clin Immunol. 2003 Jun; 111 (6): 1244–8.Bousquet J. et al. Allergy. 2008; 63 (Suppl. 86): 8–160.Bousquet J. et al. Allergy. 2008; 63 (Suppl. 86): 8–160.Levin Yu.G. et al. Voprosy sovremennoi pediatrii = Current pediatrics. 2010; 9 (6): 45–51.Левин Ю. Г. и соавт. Аллергический ринит: современные подходы к терапии. Вопросы современной педиатрии. 2010; 9 (6): 45–51.Allegra L., Paupe J., Wieseman H. G. et al. Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr. Allergy Immunol. 1993; 4 (3): 157–161.Allegra L., Paupe J., Wieseman H. G. et al. Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol. 1993; 4 (3): 157–61.Vishneva E. A., Namazova-Baranova L. S., Alexeeva A. A., Efendieva K. E., Levina Yu. G., Voznesenskaya N. I., Tomilova A. Yu., Muradova O. I., Selimzyanova L. R., Promyslova E. A. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2014; 11 (1): 6–14.Вишнёва Е. А., Намазова-Баранова Л. С., Алексеева А. А., Эфендиева К. Е., Левина Ю. Г., Вознесенская Н. И., Томилова А. Ю., Мурадова О. И., Селимзянова Л. Р., Промыслова Е. А. Современные принципы терапии аллергического ринита у детей. Педиатрическая фармакология. 2014; 11 (1): 6–14.Pearlman D. S., Lumry W. R., Winder J. A. et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebocontrolled study. Clin. Pediatr. (Phila). 1997 Apr; 36 (4): 209–215.Pearlman D. S., Lumry W. R., Winder J. A. et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr (Phila). 1997 Apr; 36 (4): 209–15.Ratner P., Gillman S., LaForce C. et al. A randomized, double blind, parallel group, placebo controlled, multicenter study of the efficacy and safety of Zyrtec (cetirizine HCL) syrup vs. Claritin (loratadine) syrup vs. placebo in the treatment of children with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2003 Jan; 90 (1): 121–122.Ratner P., Gillman S., LaForce C. et al. A randomized, double blind, parallel group, placebo controlled, multicenter study of the efficacy and safety of Zyrtec (cetirizine HCL) syrup vs. Claritin (loratadine) syrup vs. placebo in the treatment of children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003 Jan; 90 (1): 121–2.Masi M., Candiani R., van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr. Allergy Immuno. 1993; 4 (Suppl. 4): 47–52.Masi M., Candiani R., van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immuno. 1993; 4 (Suppl. 4): 47–52.Сiprandi G., Passalacqua G., Mincarini M. et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann. Allergy Asthma Immunol. 1997; 79: 507–511.Сiprandi G., Passalacqua G., Mincarini M. et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann AllergyAsthma Immunol. 1997; 79: 507–511.Lauriello M., Muzi P., Di Rienzo L. et al. A two year course of specific immunotherapy or of continuous antihistamine treatment reverses eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol. Ital. 2005; 25: 284–291.Lauriello M., Muzi P., Di Rienzo L. et al. A two year course of specific immunotherapy or of continuous antihistamine treatment reverses eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol Ital. 2005; 25: 284–291.Ciprandi G., Tosca M., Ricca V. et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin. Exp. Allergy. 1997; 27: 1160–1166.Ciprandi G., Tosca M., Ricca V. et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997; 27: 1160–1166.Ciprandi G., Tosca M. A., Milanese M. et al. Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur. Ann. Allergy Clin. Immunol. 2004; 36: 237–240.Ciprandi G., Tosca M. A., Milanese M. et al. Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur Ann Allergy Clin Immunol. 2004; 36: 237–240.Fasce L., Ciprandi G., Pronzato C. et al. Cetirizine reduces ICAM–I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int. Arch. Allergy Immunol. 1996; 109: 272–276.Fasce L., Ciprandi G., Pronzato C. et al. Cetirizine reduces ICAM–I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol. 1996; 109: 272–276.Gillman S. A., Blatter M., Condemi J. J. et al. The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin. Pediatr. (Phila). 2002 Nov–Dec; 41 (9): 687–696.Gillman S. A., Blatter M., Condemi J. J. et al. The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin Pediatr (Phila). 2002 Nov–Dec; 41 (9): 687–96.Lai D. S., Lue K. H., Hsieh J. C. et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhini tis. Ann. Allergy Asthma Immunol. 2002 Dec; 89 (6): 589–598.Lai D. S., Lue K. H., Hsieh J. C. et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhini tis. Ann Allergy Asthma Immunol. 2002 Dec; 89 (6): 589–98.Baelde Y., Dupont P. Cetirizine in children with chronic allergic rhinitis. A multicentre double-blind study of two doses of cetirizine and placebo. Drug. Invest. 1992; 4 (6): 466–472.Baelde Y., Dupont P. Cetirizine in children with chronic allergic rhinitis. A multicentre double-blind study of two doses of cetirizine and placebo. Drug Invest. 1992; 4 (6): 466–72.De Benedictis F. M., Forenza N., Armenio L. et al. Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: a 10 day, multicenter, double-blinded, randomized, parallel-group study. Pediatr. Asthma Allergy Immunol. 1997; 11 (2): 119–128.De Benedictis F. M., Forenza N., Armenio L. et al. Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: a 10 day, multicenter, double-blinded, randomized, parallel-group study. Pediatr Asthma Allergy Immunol. 1997; 11 (2): 119–28.Jobst S., van den Wijngaart W., Schubert A. et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy. 1994 Sep; 49 (8): 598–604.Jobst S., van den Wijngaart W., Schubert A. et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy. 1994 Sep; 49 (8): 598–604.Sienra-Monge J. J., Gazca-Aguilar A., Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am. J. Ther. 1999 May; 6 (3): 149–155.Sienra-Monge J. J., Gazca-Aguilar A., Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther. 1999 May; 6 (3): 149–55.Klein P. A., Clark R. A. F. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 1999; 135: 1522–1525.Klein P. A., Clark R. A. F. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999; 135: 1522–5.Wahlgren C. F., Hagermark O., Bergstrom R. The antipruritic effect of a sedative and a nonsedative antihistamine in atopic dermatitis. Br. J. Derm. 1990; 122: 545–551.Wahlgren C. F., Hagermark O., Bergstrom R. The antipruritic effect of a sedative and a nonsedative antihistamine in atopic dermatitis. Br J Derm. 1990; 122: 545–51.Hannuksela M., Kalimo K., Lammintausta K., Turjanmaa K., Vajionen E., Coulie P. J. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann. Allergy. 1993; 70: 127–133.Hannuksela M., Kalimo K., Lammintausta K., Turjanmaa K., Vajionen E., Coulie P. J. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993; 70: 127–33.Namazova-Baranova L. S., Kulichenko T. V., Borovik T. E., Makarova S. G., Novik G. A., Petrovskii F. I., Vishneva E. A., Alexeeva A. A. Atopicheskii dermatit: rukovodstvo dlya vrachei. Bolezni detskogo vozrasta ot A do Ya [Atopic Dermatitis: Guidelines for Physicians. Pediatric Diseases from A to Z]. Moscow, Pediatr, 2014. p. 40.Намазова-Баранова Л. С., Куличенко Т. В., Боровик Т. Э., Макарова С. Г., Новик Г. А., Петровский Ф. И., Вишнева Е. А., Алексеева А. А. Атопический дерматит: руководство для врачей. Болезни детского возраста от А до Я. Москва: ПедиатрЪ. 2014. С. 40.Diepgen T. L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol. 2002 Aug; 13 (4): 278–286.Diepgen T. L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002 Aug; 13 (4): 278–86.La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann. Allergy. 1994 Aug; 73 (2): 117–122.La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy. 1994 Aug; 73 (2): 117–22.Simons F. E. Prevention of acute urticaria in young children with atopic dermatitis. J. Allergy Clin. Immunol. 2001 Apr; 107 (4): 703–706.Simons F. E. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunol. 2001 Apr; 107 (4): 703–6.Ciprandi G., Frati F., Marcucci F., Sensi L., Milanese M., Tosca M. A. Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study. Eur Ann Allergy Clin. Immunology. 2003 Jun; 35 (6): 208–211.Ciprandi G., Frati F., Marcucci F., Sensi L., Milanese M., Tosca M. A. Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study. Eur Ann Allergy Clin Immunology. 2003 Jun; 35 (6): 208–11.Ciprandi G., Frati F., Marcucci F., Sensi L., Milanese M., Tosca M. A. Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study. Eur Ann Allergy Clin Immunology. 2003 Jun; 35 (6): 208–11.

The authors declare that there are no conflicts of interest present.